Trials / Completed
CompletedNCT07173738
Pharmacokinetics, Safety and Tolerability of Concurrent Doses of BIA 5-1058 and Furosemide
An Open Label, Three Period, Fixed Sequence Study to Assess the Pharmacokinetics, Safety and Tolerability of Concurrent Doses of BIA 5-1058 and Furosemide in Healthy Subjects Under Fasting Conditions.
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 44 (actual)
- Sponsor
- Bial - Portela C S.A. · Industry
- Sex
- All
- Age
- 18 Years – 55 Years
- Healthy volunteers
- Accepted
Summary
The purpose of this study is: * To assess the effect of BIA 5 1058 400 mg on furosemide pharmacokinetics (PK). * To assess the effect of furosemide 40 mg on the PK of BIA 5 1058.
Detailed description
This was an open-label, single-dose, fasted, 3-periods, fixed-sequence study separated by a washout period of 10 days or more in healthy volunteers. Each healthy subject will participate in the study for approximately 3 months, including a 28-day screening period, 3 periods of 3.5 days and 4 nights (inpatient) with each dosage separated by a 10 day washout period and a follow-up visit. The inpatient period will be from Day -1 to Day 4 morning. Dosing will occur on Day 1 and subjects will remain in the clinic until 72 hours (h) after administration. A Follow up visit will be performed 14 ± 2 days after discharge of the last period.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | BIA 5-1058 | During treatment period 1, a single oral dose of BIA 5-1058 (400 mg) will be administered on the morning of day 1, following an overnight fast of at least 10 h. |
| DRUG | Furosemide | During treatment period 2, a single oral dose of furosemide (40 mg) will be administered on the morning of day 1, following an overnight fast of at least 10 h. |
| DRUG | BIA 5-1058 and Furosemide | During treatment period 3, a single oral dose of both investigational medicinal product (IMPs) BIA 5-1058 (400 mg) concomitantly with furosemide (40 mg) will be administered on the morning of day 1, following an overnight fast of at least 10 h. |
Timeline
- Start date
- 2018-06-11
- Primary completion
- 2018-09-07
- Completion
- 2018-09-07
- First posted
- 2025-09-15
- Last updated
- 2025-09-15
Locations
1 site across 1 country: United Kingdom
Source: ClinicalTrials.gov record NCT07173738. Inclusion in this directory is not an endorsement.